Acelrx pharmaceuticals announces publication of an article highlighting the utility of the sufentanil sublingual tablet in pain medicine procedures

Hayward, calif., jan. 27, 2022 /prnewswire/ -- acelrx pharmaceuticals, inc. (nasdaq: acrx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the publication of an article reviewing the use of sufentanil sublingual tablet (sst; dsuvia ® ) for pain medicine procedures by lead author dr. sarang koushik in current pain and headache reports.
ACRX Ratings Summary
ACRX Quant Ranking